<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939468</url>
  </required_header>
  <id_info>
    <org_study_id>HYPER v2</org_study_id>
    <nct_id>NCT03939468</nct_id>
  </id_info>
  <brief_title>Drug-Coated Balloon in Combination With New Generation Drug-Eluting Stent for de Novo Diffuse Disease Treatment</brief_title>
  <acronym>HYPER</acronym>
  <official_title>A HYbrid APproach Evaluating A DRug-Coated Balloon in Combination With A New Generation Drug-Eluting Stent in the Treatment of De Novo Diffuse Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Sant'Ambrogio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Sant'Ambrogio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Pilot Observational Study to evaluate safety and efficacy of the hybrid approach DES/DCB in
      treating de-novo diffuse lesions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-randomized, single-arm, multi-center, pilot, noninterventional
      study whose aim is to assess the feasibility and the clinical outcomes of using the Restore
      DCB (Cardionovum GmbH, Bonn, Germany) in combination (&quot;hybrid approach&quot;) with a new
      generation DES (type at operator's discretion) for the treatment of diffuse CAD encountered
      in daily clinical practice. The rationale of the proposed strategy derives from the
      characteristics of DCB in treating the atherosclerotic disease without leaving a permanent
      structure in the vessel especially in case of diffuse CAD -avoiding a long metallic,
      permanent cage within extended coronary segments
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>DOCE at 12 Months</measure>
    <time_frame>12 Months</time_frame>
    <description>A device oriented composite end-point (DOCE) of cardiac death, target vessel myocardial infarction (TV-MI) and ischemia-driven target lesion revascularization (ID-TLR) in the DES- and/or the DCB-treated segment within 12 months after the index procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>At procedure</time_frame>
    <description>Procedural success defined as both DCB/DES delivery and implantation at the &quot;target&quot; lesion site with &lt;30% diameter stenosis (DS) in the DCB-treated segment and &lt;10% DS in the DES-treated segment and distal TIMI 3 flow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural myocardial infarction</measure>
    <time_frame>Pre-discharge</time_frame>
    <description>Peri-procedural myocardial infarction defined as an elevation of cardiac biomarkers (troponin or creatine kinase-myocardial band) &gt;3 times the upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOCE</measure>
    <time_frame>Pre-discharge, 30 days, 6 months, 12 months</time_frame>
    <description>DOCE and its singular components (cardiac death, any TV-MI excluding peri-procedural MI, ID-TLR ) in-hospital, (within 7 days after PCI) and at 30-day, 6-month, 1-year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Any definite/probable DES- or DCB-treated segment thrombosis (in-hospital, within 7 days after PCI and at 30-day, 6month, 1-year follow-up).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow-limiting dissection</measure>
    <time_frame>12 months</time_frame>
    <description>Flow-limiting dissection (type C-F waiting 3 minutes after DCB inflation) requiring additional DES implantation in the DCB-treated segment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Observational Cohort</arm_group_label>
    <description>Patient with diffuse CAD disease treated with hybrid strategy (DES+DCB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DES+DCB</intervention_name>
    <description>A hybrid strategy is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES implantation for a de novo lesion (located in the larger, more proximal part of the vessel) and DCB inflation for a concomitant de novo small vessel disease</description>
    <arm_group_label>Observational Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stable or unstable CAD eligible for PCI (according to International
        guidelines) due to diffuse disease (located in the same vessel) suitable for a &quot;hybrid
        approach&quot; (see below) will be enrolled after signing the informed consent. A hybrid
        strategy was defined as overlapping or slightly (2-3 mm) superimposing a new generation DES
        implantation for a de novo lesion (located in the larger, more proximal part of the vessel)
        and DCB inflation for a concomitant de novo small vessel disease (located in the smaller
        distal segment or at a side branch of a bifurcation in the same coronary artery). Diffuse
        disease is defined as CAD≥28 mm in length involving distal segments or side branches of a
        bifurcation lesion with a reference vessel diameter (RVD) considered suitable for a hybrid
        approach in case of ≥2.75 mm RVD for a DEStarget segment and ≥2.0 mm to &lt;2.75 mm RVD for a
        DCB-target segment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting with stable or unstable CAD eligible for PCI (according to the
             international guidelines) because of diffuse CAD involving segments suitable for a
             hybrid approach;

          -  Signed Patient Informed Consent/Data Release Form

        Exclusion Criteria:

          1. Age &lt;18 years;

          2. Cardiogenic shock;

          3. Pregnancy or breastfeeding;

          4. Infarct-artery max diameter (within planned device deployment segment) &lt;2.0 or &gt;5.0
             mm;

          5. Comorbidities with life expectancy &lt;6 months;

          6. Severe calcification or/tortuosity proximally or at the DCB target segment;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Rho</name>
      <address>
        <city>Rho</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giuseppe De Angelis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe De Angelis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susanna Benincasa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico S.Anna</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Delio Tedeschi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Delio Tedeschi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Ospedale Cremona</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Marco Loffi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marco Loffi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico S.Ambrogio</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alfonso Ielasi, MD</last_name>
      <email>alielasi@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Alfonso Ielasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Costopoulos C, Latib A, Naganuma T, Sticchi A, Figini F, Basavarajaiah S, Carlino M, Chieffo A, Montorfano M, Naim C, Kawaguchi M, Giannini F, Colombo A. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease. JACC Cardiovasc Interv. 2013 Nov;6(11):1153-9. doi: 10.1016/j.jcin.2013.07.005.</citation>
    <PMID>24262615</PMID>
  </reference>
  <reference>
    <citation>Ielasi A, Miyazaki T, Geraci S, Testa L, Abdel-Wahab M, Kawamoto H, Ruparelia N, Sato T, Caramanno G, Bedogni F, Tespili M, Colombo A, Latib A. Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease: the &quot;no more metallic cages&quot; multicentre pilot experience. EuroIntervention. 2016 Apr 8;11(14):e1589-95. doi: 10.4244/EIJV11I14A309.</citation>
    <PMID>27056119</PMID>
  </reference>
  <reference>
    <citation>Tang Y, Qiao S, Su X, Chen Y, Jin Z, Chen H, Xu B, Kong X, Pang W, Liu Y, Yu Z, Li X, Li H, Zhao Y, Wang Y, Li W, Tian J, Guan C, Xu B, Gao R; RESTORE SVD China Investigators. Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease: The RESTORE SVD China Randomized Trial. JACC Cardiovasc Interv. 2018 Dec 10;11(23):2381-2392. doi: 10.1016/j.jcin.2018.09.009.</citation>
    <PMID>30522667</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Sant'Ambrogio</investigator_affiliation>
    <investigator_full_name>ALFONSO IELASI</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Drug Coated Balloons</keyword>
  <keyword>Drug Eluting Stent</keyword>
  <keyword>Diffuse Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

